Author: Ravi Shankar

A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program

VP of Product Development Liz Proos presents Friday, October 30, at 2:30 p.m. ET in Boston

SAN DIEGO, Oct. 26, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that Liz Proos, Vice President of Product Development of Daré Bioscience, will present on the Company’s Intelligent Drug Delivery System (DARE-IDDS) at the 16th annual Partnership Opportunities in Drug Delivery (PODD) conference, one of the leading drug delivery industry conferences, taking place October 29–30, 2026 in Boston, MA.

Ms. Proos will present “Expanding Chronic Therapy Adherence with a Single Programmable Device” on Friday, October 30, from 2:30 to 2:50 p.m. ET. The presentation will highlight the potential of DARE-IDDS to address challenges associated with long-term and chronic injection-based therapies by combining programmable drug delivery, wireless communication and dosing flexibility within a single subcutaneously implanted device.

Millions of patients on chronic therapies depend on repeated injections, frequent clinic visits and the discipline to stay on schedule. When patients miss doses, the benefits of even highly effective medicines can be lost. DARE-IDDS is designed to take that burden off the patient.

DARE-IDDS is a single device, implantable under the skin, that is designed to:

• Store and deliver more than 100 discrete doses over periods ranging from months to years
• Program each dose electronically, using independent drug reservoirs and electronic dose control
• Connect wirelessly, with the potential to let patients and healthcare providers monitor and adjust treatment remotely
• Reduce treatment burden, potentially cutting the need for repeated injections, frequent clinic visits and ongoing medication management

By combining extended drug storage with programmable delivery and patient control, DARE-IDDS is being developed to support a range of potential therapeutic applications. The technology is initially being targeted for contraception through Daré Bioscience’s DARE-LARC1 program, which is being developed with the goal of providing a long-acting, reversible contraceptive option designed to give women greater flexibility in managing their reproductive journey. Because DARE-IDDS is a platform, Daré Bioscience believes it may also have applications across other therapeutic areas where adherence, treatment burden and reliable dosing are significant issues, and where future development and commercial partners may see value.

“DARE-IDDS represents an opportunity to rethink how medications are delivered over the long term, particularly in therapeutic areas where adherence and treatment burden can limit the benefits of available therapies,” said Ms. Proos. “By bringing together programmable dosing, wireless connectivity and patient control in a single implantable device platform, we are working to advance a more flexible approach to drug delivery that has the potential to benefit patients, healthcare providers and future development and commercial partners.”

Daré Bioscience has collaborated with Cambridge Consultants, a global product development and technology consultancy, to advance the DARE-IDDS platform, combining drug delivery expertise with capabilities in implantable electronics, connectivity and device engineering. The collaboration reflects Daré Bioscience’s focus on advancing differentiated technology designed to address unmet needs and create new possibilities for patient-centered care.

DARE-IDDS is an investigational device in preclinical development. It has not been approved or cleared for clinical investigation in humans or for any use in humans. The DARE-IDDS features described in this press release are based on the results of technological proof-of-concept studies.

ABOUT DARÉ BIOSCIENCE, INC.

Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com.

FORWARD-LOOKING STATEMENTS

Daré Bioscience cautions you that all statements, other than statements of historical facts, contained in this press release are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “prepare,” “progress,” “seek,” “should,” “would,” “build” or the negative version of these words and similar expressions.

In this press release, forward-looking statements include, but are not limited to, statements relating to: the potential capabilities of DARE-IDDS as part of a therapeutic product for humans, including storing and delivering more than 100 discrete doses over periods ranging from months to years, electronic dose programming, and wireless connectivity enabling remote treatment monitoring and adjustment; the potential of DARE-IDDS to improve treatment adherence and reduce treatment burden; the potential application of DARE-IDDS in a broad range of therapeutic areas; the therapeutic and market potential of future products utilizing DARE-IDDS; continued development of DARE-LARC1 and its potential to demonstrate safety and effectiveness as a long-acting reversible contraceptive product; and the potential for Daré Bioscience to enter into strategic collaborations for development and commercialization of therapeutic products utilizing DARE-IDDS.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré Bioscience’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: advancing DARE-LARC1 and any future product candidate utilizing DARE-IDDS through preclinical stage development and into human clinical trials; the ability of product candidates utilizing DARE-IDDS to demonstrate acceptable safety, tolerability and efficacy, including contraceptive effectiveness, in humans; the potential that product candidates utilizing DARE-IDDS may not demonstrate the dose capacity, duration of drug storage and delivery, or wireless connectivity and remote treatment monitoring and adjustment functionality anticipated based on technological proof-of-concept studies of DARE-IDDS; the risk that positive findings in technological proof-of-concept studies, other nonclinical studies and/or early clinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; delays, increased costs, or failure in completing necessary nonclinical and clinical studies of a product candidate, including due to unanticipated requirements for additional testing; potentially more complex, costly or lengthy development and approval requirements for drug-device combination product candidates; delays or failure to obtain U.S. Food and Drug Administration (FDA) or foreign regulatory approval for a product candidate; achieving anticipated treatment adherence or reduction in treatment burden benefits with any DARE-IDDS-based product, if approved; difficulties establishing and maintaining relationships with development and/or commercial collaborators; Daré Bioscience’s dependence on third parties to conduct nonclinical and clinical studies and manufacture and supply clinical trial material and commercial product, and the performance and resource commitments of such third parties; difficulties in manufacturing drug product candidates and their components at the required quality, stability and scale for clinical trials and commercialization; Daré Bioscience’s ability to obtain additional capital when and as needed to execute its business strategy and continue as a going concern; dependence on grants and other financial awards from governmental entities and a private foundation and the risk that such funding may be reduced, delayed, or terminated, or may be insufficient to advance a product candidate into or through a particular stage of development as anticipated; potential suspension and delisting of Daré Bioscience’s common stock from The Nasdaq Capital Market; failure of any products, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors; the risk that developments by competitors make Daré Bioscience’s products or product candidates less competitive or obsolete; Daré Bioscience’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré Bioscience’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive in-license agreements covering the critical patents and related intellectual property related to its products and product candidates; Daré Bioscience’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré Bioscience’s product candidates, which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Daré Bioscience’s products or product candidates or the business activities of Daré Bioscience, its commercial collaborators or other third parties on which Daré Bioscience relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Daré Bioscience’s ability to raise additional capital or on Daré Bioscience’s operations, financial results and condition, and ability to achieve current plans and objectives; and cybersecurity incidents or similar events that compromise Daré Bioscience’s technology systems and/or significantly disrupt Daré Bioscience’s business or those of third parties on which Daré Bioscience relies.

Daré Bioscience’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré Bioscience’s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission (SEC), including Daré Bioscience’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré Bioscience undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contact:
Daré Bioscience Investor Relations
innovations@darebioscience.com

Source: Daré Bioscience, Inc.

New platform connects domain experts with mission-critical AI work as companies compete for the human expertise needed to move AI from innovation to execution

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) — iMerit, an EXL company, today announced the launch of its iMerit Scholars platform, designed to seamlessly manage hundreds of thousands of global domain experts (Scholars) who work on fine-tuning, evaluation and validation of generative AI models. This represents the first major launch since EXL (Nasdaq: EXLS) acquired iMerit in July to accelerate the progression of frontier AI into regulated enterprises.

The launch comes as the AI talent war heats up across generative and physical AI. The iMerit Scholars program already brings together a curated global community of 30,000 domain experts and linguists to support advanced model training, evaluation, validation and safety across specialized fields. The new iMerit Scholars platform provides a unified system to recruit, onboard, curate, assign, manage, engage, pay, and retain these experts at scale. It is powered by iMerit’s proprietary Ango Hub, which allows customers and experts to collaborate on complex multimodal data to generate highly curated and validated training artifacts for high-stakes models. 

“iMerit has always differentiated itself by a curated, people-first approach. We’re seeing that become even more important as we scale up to help the frontier labs,” said Radha Basu, executive vice president, head of iMerit at EXL. “The next phase of the GenAI race is about creating a painless and supportive infrastructure so that these highly capable specialists can enjoy their work and give their best. Scaling high quality and high engagement is mainly a human capital opportunity, backed by enabling technology. The iMerit Scholars platform is designed to create a seamless experience for top-notch talent to continue building and improving the next generation of AI.”

“Now, as a part of EXL, we are expanding from the creation of models in frontier labs to the implementation of model workflows in highly regulated enterprises in banking, healthcare and insurance. Once again, we find that trust, safety, and last-mile customization will dictate the success of AI projects in these sectors. We need people who are knowledgeable enough not just to teach models, but to prove them wrong and correct them. That parallel human authority is what will help move AI from innovation to trusted execution,” added Basu.

Leveraging Trolley’s global payouts platform, iMerit Scholars incorporates compliance and global secure payments to create a mutually beneficial environment for customers and experts. 

The iMerit Scholars program was built to meet the need for structured reasoning, domain nuance, and ongoing evaluation across high-stakes use cases in healthcare, physical AI, finance, and foundation models. The iMerit Scholars community brings together over 30,000 invited and vetted professionals from 118 countries representing 106 languages across fields such as medicine, mathematics, agriculture, linguistics, and autonomous systems. iMerit works with them to test, challenge, and “torment” models, helping improve performance in real-world conditions through techniques like RLHF, red-teaming, Q&A prompting, chain-of-thought tracing, and evaluation.

The iMerit Scholars platform matches experts with projects aligned to their specialization, enabling more consistent engagement and higher-quality outcomes. iMerit Scholars platform also introduces new capabilities to support this evolving workforce model, including:

• Expert matching based on domain specialization and cognitive skill sets
• Secure, compliant workflows for sensitive data environments
• Global payments and workforce infrastructure through Trolley
• Integrated tooling for training, evaluation, and model feedback loops

For experts, iMerit Scholars platform represents a move from fragmented experiences to a meaningful, ongoing relationship.

“Working with AI in this way feels like contributing to something foundational,” said Pavel Kopach, M.D. Department of Pathology, Beth Israel Deaconess Medical Center, and iMerit Scholar in Healthcare AI. “You’re not just labeling data, you’re helping shape how these systems reason and behave in your field. That’s both challenging and incredibly rewarding.”

To learn more about iMerit, an EXL company, visit iMerit.ai.

About EXL

EXL (NASDAQ: EXLS) is a global data and AI company that offers services and solutions to reinvent client business models, drive better outcomes and unlock growth with speed. EXL harnesses the power of data, AI, and deep industry knowledge to transform businesses, including the world’s leading corporations in industries including insurance, healthcare, banking and capital markets, retail, communications and media, and energy and infrastructure, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have approximately 68,000 employees spanning six continents. For more information, visit www.exlservice.com.

Media Contact: imerit@inkhouse.com 

GEORGE TOWN, Grand Cayman, Oct. 26, 2026 (GLOBE NEWSWIRE) — Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water treatment plants, will hold a conference call on Tuesday, November 10, 2026 at 11:00 a.m. Eastern time to discuss its results for the third quarter ended September 30, 2026.

The financial results will be issued in a press release prior to the call. Consolidated Water management will host the call, followed by a question-and-answer period.

Date: Tuesday, November 10, 2026
Time: 11:00 a.m. Eastern time (8:00 a.m. Pacific time)
Toll-free dial-in number: 1-844-875-6913
International dial-in number: 1-412-317-6709
Participant web phone: click here

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you require any assistance connecting with the call, please contact Encore at 1-949-432-7450.

A replay of the call will be available after 1:00 p.m. Eastern time on the same day through November 17, 2026, as well as available for replay via the Investors section of the Consolidated Water website at www.cwco.com.

Toll-free replay number: 1-855-669-9658
International replay number: 1-412-317-0088
Replay ID: 5866966

About Consolidated Water Co. Ltd.
Consolidated Water Co. Ltd. develops and operates advanced water treatment plants and water distribution systems. The company designs, constructs and operates seawater desalination facilities in the Cayman Islands, The Bahamas and the British Virgin Islands, and designs, constructs and operates water treatment and reuse facilities in the United States.

The company also manufactures and services a wide range of products and provides design, engineering, management, operating and other services applicable to commercial and municipal water production, supply and treatment, and industrial water and wastewater treatment.

For more information, visit cwco.com.

Company Contact:
David W. Sasnett
Executive Vice President and CFO
Tel (954) 509-8200
Email Contact

Investor & Media Contact:
Ron Both or Grant Stude
Encore Investor Relations
Tel (949) 432-7450
Email Contact

BATON ROUGE, La., Oct. 26, 2026 (GLOBE NEWSWIRE) — Business First Bancshares, Inc. (NASDAQ: BFST) (Business First), parent company of b1BANK, today announced its unaudited results for the quarter ended September 30, 2026. Business First reported net income available to common shareholders of $23.2 million or $0.71 per diluted common share, increases of $0.4 million and $0.01, respectively, compared to the linked quarter. On a non-GAAP basis, core net income available to common shareholders for the quarter ended September 30, 2026, which excludes certain income and expenses, was $26.0 million or $0.79 per diluted common share, increases of $2.7 million and $0.08 from the linked quarter.

“Our third quarter showed what disciplined execution can deliver,” said Jude Melville, chairman, president, and CEO of Business First. “We completed the conversion of Progressive Bank, and I’m grateful to our North Louisiana teammates and clients for helping make it a seamless transition. We grew loans and deposits at a balanced pace appropriate to our level of capital strength, and we did so while expanding our net interest margin by 12 basis points and keeping non-interest expenses in check. The result was higher earnings and stronger returns. Our team earned these results through disciplined execution, and we’ll keep that same focus as we continue to invest in the growing number of opportunities we’re seeing across our diversified footprint.”

On Thursday, October 22, 2026, Business First’s board of directors declared a quarterly preferred dividend in the amount of $18.75 per share, which is the full quarterly dividend of 1.875% based on the per annum rate of 7.50%. Additionally, the board of directors declared a quarterly common dividend based upon financial performance for the third quarter in the amount of $0.15 per share of common stock. The preferred and common dividends will be paid on November 30, 2026, or as soon thereafter as practicable, to the shareholders of record as of November 15, 2026.

Quarterly Highlights

• Improving Core Performance. Return to common shareholders on average assets, on an annualized basis, was 1.04% for the quarter ended September 30, 2026, or 1.17% on a non-GAAP basis, compared to 1.03% or 1.05% on a non-GAAP basis for the linked quarter. Return to common shareholders on average equity on an annualized basis, was 9.75% for the quarter ended September 30, 2026, or 10.93% on a non-GAAP basis, compared to 9.83%, or 10.05% on a non-GAAP basis for the linked quarter.
• Margin Expansion. Net interest margin expanded 13 basis points (bps) to 3.86% for the quarter ended September 30, 2026, or 12 bps to 3.80% on a non-GAAP basis, respectively, compared to 3.73% or 3.68%, respectively, for the linked quarter. The expansion was driven by improvement in book yield on loans and a reduction in the overall cost of funding. The reduction in overall cost of funding was driven by decreases of $65.9 million in brokered deposits and $107.8 million in borrowings while core deposit costs remained flat.
• Loan and Deposit Growth. Loans grew by $121.4 million or 7.23%, annualized and deposits grew by $141.2 million or 7.74% annualized, led by our Houston, Texas and Southwest Louisiana markets.
• Capital and Share Repurchases. During the third quarter, as part of a previously announced stock repurchase program, Business First repurchased 204,160 shares, with a market value of $6.3 million, at a weighted average price of $30.81 per share. Common equity to total assets decreased from 10.52% to 10.39%. Business First has repurchased a total of 630,618 common shares under the existing stock repurchase program, since October 2025, or $17.6 million at a weighted average repurchase price per share of $27.88.
• Progressive Conversion. In August 2026, Business First successfully converted Progressive Bank’s core systems onto its platform.

Statement of Financial Condition

Loans

Loans held for investment increased $121.4 million or 1.82%, 7.23% annualized, compared to the linked quarter. The commercial real estate and construction portfolios increased $72.7 million and $80.7 million, respectively, compared to the linked quarter. The residential real estate portfolio decreased $30.6 million compared to the linked quarter.

Credit Quality

Loans over 30 days past due at September 30, 2026 were $32.5 million or 0.48% of total loans, which was generally stable from the linked quarter. The ratio of nonperforming loans compared to loans held for investment decreased 2 bps to 1.24% at September 30, 2026, while the ratio of nonperforming assets compared to total assets also decreased by 1 bps to 1.22% compared to the linked quarter. Net charge-offs to average quarterly total loans increased to 8 bps for the quarter ended September 30, 2026, up from 4 bps in the linked quarter mainly attributable to one previously fully reserved commercial relationship.

Securities

The securities portfolio decreased $54.4 million or 5.23%, from the linked quarter, impacted by $24.2 million in negative pre-tax fair value adjustments and the remainder of the decrease attributed to maturities and paydowns. The securities portfolio, based on estimated fair value, represented 11.02% of total assets as of September 30, 2026.

Deposits

Deposits as of September 30, 2026 increased by $141.2 million or 1.95%, 7.74% annualized, compared to the linked quarter. During the third quarter, interest-bearing deposits increased $119.1 million or 2.11% and noninterest-bearing deposits increased $22.1 million or 1.40%. The increase in interest-bearing deposits was attributable to $180.1 million in commercial money market accounts, partially offset by a decrease of $65.9 million in brokered deposits. Average interest-bearing deposits decreased $9.5 million or 0.16%, and noninterest-bearing deposits increased $54.9 million or 3.62% from the linked quarter.

Borrowings

Borrowings decreased $107.8 million or 18.25%, from the linked quarter due primarily to decreases in short-term Federal Home Loan Bank advances.

Shareholders’ Equity

On a non-GAAP basis, tangible book value per common share increased from $23.61 at the linked quarter to $23.71 at September 30, 2026, 0.42% or 1.66% annualized, despite the negative pre-tax fair value adjustments. Shareholders’ equity decreased $6.1 million or 0.60% compared to the linked quarter. Accumulated other comprehensive loss increased from $35.8 million to $54.9 million or 53.29%, during the quarter due to after-tax fair value adjustments in the securities portfolio. Book value per common share decreased to $28.77 at September 30, 2026, compared to $28.79 from the linked quarter.

Results of Operations

Net Interest Income

For the quarter ended September 30, 2026, net interest income totaled $80.7 million, compared to $77.8 million from the linked quarter. Loan yields increased 11 bps to 6.74% compared to 6.63% from the linked quarter and interest-bearing asset yields increased 8 bps to 6.10% compared to 6.02% from the linked quarter. Net interest margin and net interest spread were 3.86% and 3.09% compared to 3.73% and 2.99% for the linked quarter. The overall cost of funds, which included noninterest-bearing deposits, decreased 4 bps from 2.44% to 2.40% for the quarter ended September 30, 2026.

Non-GAAP net interest income (excluding loan discount accretion of $1.2 million) totaled $79.4 million for the quarter ended September 30, 2026, compared to $76.8 million (excluding loan discount accretion of $1.0 million) for the linked quarter. Non-GAAP net interest margin and net interest spread (excluding loan discount accretion of $1.2 million) were 3.80% and 3.04%, respectively, for the quarter ended September 30, 2026, compared to 3.68% and 2.94% (excluding loan discount accretion of $1.0 million) for the linked quarter.

Provision for Credit Losses

During the quarter ended September 30, 2026, Business First recorded a provision for credit losses of $1.9 million, compared to $2.0 million from the linked quarter. At September 30, 2026, the ratio of allowance for credit losses to loans held for investment was 0.95%, compared to 1.02% for the linked quarter.

Other Income

For the quarter ended September 30, 2026, other income decreased $1.5 million or 10.42%, compared to the linked quarter. The decrease was largely attributable to a $0.8 million decrease in gain on sales of loans and the linked quarter’s $0.5 million gain on the redemption of debt.

Other Expenses

For the quarter ended September 30, 2026, other expenses increased $0.9 million or 1.58% compared to the linked quarter. The increase was largely attributable to increases of $1.8 million in occupancy and equipment expense and $1.1 million in merger and conversion-related expenses, partially offset by decreases of $0.5 million in each in advertising and promotions expense and salaries and employee benefits, $0.4 million in legal and other professional fees and $0.3 million in regulatory assessments. The increase in occupancy and equipment expense was largely attributable to a lease termination fee associated with better alignment of legacy b1BANK and Progressive corporate facilities.

Return on Assets and Common Equity

Return to common shareholders on average assets and common equity, each on an annualized basis, were 1.04% and 9.75% for the quarter ended September 30, 2026, compared to 1.03% and 9.83%, respectively, for the linked quarter. Non-GAAP return to common shareholders on average assets and common equity, each on an annualized basis, were 1.17% and 10.93% for the quarter ended September 30, 2026, compared to 1.05% and 10.05% for the linked quarter.

Conference Call and Webcast

Executive management will host a conference call and webcast to discuss results on Monday, October 26, 2026, at 9:00 a.m. Central Time. Interested parties may attend the call by dialing toll-free 1-800-715-9871 (North America only), conference ID 8846141, or asking for the Business First Bancshares conference call. The live webcast can be found at https://edge.media-server.com/mmc/p/uhshyz4m. On the day of the presentation, the corresponding slide presentation will be available to view on the b1BANK website at https://www.b1bank.com/shareholder-info.

About Business First Bancshares, Inc.

Business First Bancshares, Inc. (Nasdaq: BFST), through its banking subsidiary b1BANK, has $8.9 billion in assets, $5.5 billion in assets under management through b1BANK’s affiliate Smith Shellnut Wilson, LLC (SSW) (not including $1.0 billion of b1BANK assets managed by SSW) and operates Banking Centers and Loan Production Offices in markets across Louisiana and Texas, providing commercial and personal banking products and services. b1BANK is a 2024 Mastercard “Innovation Award” winner and multiyear winner of American Banker Magazine’s “Best Banks to Work For.” Visit b1BANK.com for more information.

Non-GAAP Financial Measures

This press release includes certain non-GAAP financial measures (e.g., referenced as “core” or “tangible”) intended to supplement, not substitute for, comparable GAAP measures. “Core” measures typically adjust income available to common shareholders for certain significant activities or transactions that, in management’s opinion, can distort period-to-period comparisons of Business First’s performance. Transactions that are typically excluded from non-GAAP “core” measures include realized and unrealized gains/losses on former bank premises and equipment, investment sales, acquisition-related expenses (including, but not limited to, legal costs, system conversion costs, severance and retention payments, etc.). “Tangible” measures adjust common equity by subtracting goodwill, core deposit intangibles, and customer intangibles, net of accumulated amortization. Management believes presentations of these non-GAAP financial measures provide useful supplemental information that is essential to a proper understanding of the operating results of Business First’s core business. These non-GAAP disclosures are not necessarily comparable to non-GAAP measures that may be presented by other companies. Reconciliations of non-GAAP financial measures to GAAP financial measures are provided at the end of the tables below.

Special Note Regarding Forward-Looking Statements

Certain statements contained in this release may not be based on historical facts and are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by their reference to a future period or periods or by the use of forward-looking terminology such as “anticipate,” “believe,” “estimate,” “expect,” “may,” “might,” “will,” “would,” “could,” or “intend.” We caution you not to place undue reliance on the forward-looking statements contained in this news release, in that actual results could differ materially from those indicated in such forward-looking statements as a result of a variety of factors, including those factors specified in our Annual Report on Form 10-K and other public filings. We undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date of this news release.

Additional Information

For additional information about Business First, you may obtain Business First’s reports that are filed with the Securities and Exchange Commission (SEC) free of charge by using the SEC’s EDGAR service on the SEC’s website at www.SEC.gov or by contacting the SEC for further information at 1-800-SEC-0330. Alternatively, these documents can be obtained free of charge from Business First by directing a request to: Business First Bancshares, Inc., 500 Laurel Street, Suite 101, Baton Rouge, Louisiana 70801, Attention: Corporate Secretary.

No Offer or Solicitation

This release does not constitute or form part of any offer to sell, or a solicitation of an offer to purchase, any securities of Business First. There will be no sale of securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Investor Relations Contacts:

Gregory Robertson 337.721.2701
Gregory.Robertson@b1bank.com

Matt Sealy 225.388.6116
Matt.Sealy@b1bank.com

Business First Bancshares, Inc.
Selected Financial Information
(Unaudited)
	Three Months Ended
	September 30,			June 30,			September 30,
(Dollars in thousands)		2026			2026			2025
Balance Sheet Ratios
Loans (HFI) to Deposits		91.92	%		92.04	%		92.53	%
Shareholders’ Equity to Assets Ratio		11.19	%		11.33	%		11.04	%
Loans Receivable Held for Investment (HFI)
Commercial	$	1,990,998		$	1,988,696		$	1,920,813
Real Estate:
Commercial		2,896,707			2,824,015			2,462,617
Construction		774,170			693,477			638,907
Residential		1,048,400			1,079,018			927,456
Total Real Estate		4,719,277			4,596,510			4,028,980
Consumer and Other		70,612			74,241			71,262
Total Loans (Held for Investment)	$	6,780,887		$	6,659,447		$	6,021,055
Allowance for Loan Losses
Balance, Beginning of Period	$	62,458		$	63,655		$	58,496
Charge-offs – Quarterly		(5,787	)		(3,208	)		(3,415	)
Recoveries – Quarterly		284			293			348
Provision for Loan Losses – Quarterly		2,640			1,718			1,633
Balance, End of Period	$	59,595		$	62,458		$	57,062
Allowance for Loan Losses to Total Loans (HFI)		0.88	%		0.94	%		0.95	%
Allowance for Credit Losses to Total Loans (HFI) (1)		0.95	%		1.02	%		1.03	%
Net Charge-offs to Average Quarterly Total Loans		0.08	%		0.04	%		0.05	%
Remaining Loan Purchase Discount	$	6,119		$	7,341		$	8,943
Nonperforming Assets
Nonperforming Loans:
Nonaccrual Loans	$	80,363		$	80,124		$	45,362
Loans Past Due 90 Days or More		3,701			4,011			3,929
Total Nonperforming Loans		84,064			84,135			49,291
Other Nonperforming Assets:
Other Real Estate Owned		24,761			25,109			16,766
Other Nonperforming Assets		—			—			—
Total Other Nonperforming Assets		24,761			25,109			16,766
Total Nonperforming Assets	$	108,825		$	109,244		$	66,057
Nonperforming Loans to Total Loans (HFI)		1.24	%		1.26	%		0.82	%
Nonperforming Assets to Total Assets		1.22	%		1.23	%		0.83	%
(1) Allowance for Credit Losses includes the Allowance for Loan Loss and Reserve for Unfunded Commitments.

Business First Bancshares, Inc.
Selected Financial Information
(Unaudited)
	Three Months Ended										Nine Months Ended
	September 30,			June 30,			September 30,				September 30,			September 30,
(Dollars in thousands, except per share data)		2026			2026			2025				2026			2025
Per Share Data
Basic Earnings per Common Share	$	0.71		$	0.70		$	0.73			$	2.10		$	2.09
Diluted Earnings per Common Share		0.71			0.70			0.73				2.08			2.08
Dividends per Common Share		0.15			0.15			0.14				0.45			0.42
Book Value per Common Share		28.77			28.79			27.23				28.77			27.23
Average Common Shares Outstanding		32,504,217			32,589,951			29,544,425				32,558,017			29,363,138
Average Diluted Common Shares Outstanding		32,730,923			32,763,608			29,656,639				32,766,628			29,495,049
End of Period Common Shares Outstanding		32,345,723			32,535,659			29,615,370				32,345,723			29,615,370
Annualized Performance Ratios
Return to Common Shareholders on Average Assets (1)		1.04	%		1.03	%		1.08	%			1.03	%		1.05	%
Return to Common Shareholders on Average Common Equity (1)		9.75	%		9.83	%		10.80	%			9.78	%		10.74	%
Net Interest Margin (1)		3.86	%		3.73	%		3.68	%			3.75	%		3.68	%
Net Interest Spread (1)		3.09	%		2.99	%		2.85	%			3.00	%		2.88	%
Efficiency Ratio (2)		64.88	%		64.83	%		60.45	%			64.72	%		62.37	%
Total Quarterly/Year-to-Date Average Assets	$	8,845,047		$	8,916,954		$	7,921,159			$	8,886,084		$	7,825,828
Total Quarterly/Year-to-Date Average Common Equity		944,333			931,020			790,148				932,545			764,959
Other Expenses
Salaries and Employee Benefits	$	32,582		$	33,120		$	27,613			$	98,741		$	85,427
Occupancy and Equipment Expense		10,078			8,279			7,284				26,479			21,802
Advertising and Promotions		2,064			2,606			1,205				6,178			3,584
Communications		773			638			582				2,063			1,763
Ad Valorem Shares Tax		978			977			1,125				2,933			3,375
Data Processing Fees		3,084			3,317			3,972				10,113			12,529
Directors’ Fees		308			247			261				815			733
Insurance		188			432			420				1,031			1,248
Legal and Professional Fees		1,236			1,661			1,024				3,982			3,130
Office Supplies and Printing		268			278			286				859			897
Regulatory Assessments		1,209			1,534			1,142				3,727			3,332
Merger and Conversion-Related Expenses		1,395			303			477				3,075			937
Other		6,302			6,133			3,491				17,465			11,909
Total Other Expenses	$	60,465		$	59,525		$	48,882			$	177,461		$	150,666
Other Income
Service Charges on Deposit Accounts		3,340			3,197			2,565				9,679			8,058
Gain (Loss) on Sales of Securities		(21	)		(6	)		77				53			29
Gain on Sales of Loans		814			1,583			624				3,738			2,661
Debit Card and ATM Fee Income		2,380			2,415			1,915				7,101			5,731
Cash Value of Life Insurance Income		979			902			802				2,712			2,368
Fees and Brokerage Commission		2,458			2,387			1,880				7,106			6,008
Pass-Through Income (Loss) from Other Investments		(135	)		14			133				14			638
Gain on Extinguishment of Debt		—			545			—				545			630
Gain on Sale of Branch		—			—			—				—			3,360
Swap Fee Income		626			385			1,065				2,548			2,612
Other		2,071			2,545			2,610				7,033			7,217
Total Other Income	$	12,512		$	13,967		$	11,671			$	40,529		$	39,312
(1) Average outstanding balances are determined utilizing daily averages and average yield/rate is calculated utilizing an actual day count convention.
(2) Noninterest expense (excluding provision for loan losses) divided by noninterest income plus net interest income less gain/loss on sales of securities.

Business First Bancshares, Inc.
Consolidated Balance Sheets
(Unaudited)
	September 30,			June 30,			September 30,
(Dollars in thousands)		2026			2026			2025
Assets
Cash and Due From Banks	$	490,037		$	575,604		$	399,079
Federal Funds Sold		110,738			95,535			101,103
Securities Purchased Under Agreements to Resell		79,214			30,702			25,518
Securities Available for Sale, at Fair Values		986,704			1,041,133			985,938
Mortgage Loans Held for Sale		254			2,838			433
Loans and Lease Receivable		6,780,887			6,659,447			6,021,055
Allowance for Loan Losses		(59,595	)		(62,458	)		(57,062	)
Net Loans and Lease Receivable		6,721,292			6,596,989			5,963,993
Premises and Equipment, Net		95,456			88,925			77,944
Accrued Interest Receivable		39,321			38,969			37,171
Other Equity Securities		39,984			51,302			44,313
Other Real Estate Owned		24,761			25,109			16,766
Cash Value of Life Insurance		140,148			139,169			119,509
Deferred Taxes, Net		24,853			21,561			21,433
Goodwill		131,743			135,222			121,146
Core Deposit and Customer Intangibles		31,983			33,267			15,136
Other Assets		39,474			27,181			24,380
Total Assets	$	8,955,962		$	8,903,506		$	7,953,862
Liabilities
Deposits
Noninterest-Bearing	$	1,605,682		$	1,583,562		$	1,366,558
Interest-Bearing		5,771,116			5,651,994			5,140,304
Total Deposits		7,376,798			7,235,556			6,506,862
Securities Sold Under Agreements to Repurchase		24,896			24,442			29,896
Other Short Term Borrowings		—			—			—
Federal Home Loan Bank Borrowings		334,189			442,494			367,408
Subordinated Debt		114,250			114,250			92,587
Subordinated Debt – Trust Preferred Securities		9,689			9,678			5,000
Accrued Interest Payable		3,126			3,774			4,064
Other Liabilities		90,498			64,735			69,605
Total Liabilities		7,953,446			7,894,929			7,075,422
Shareholders’ Equity
Preferred Stock		71,930			71,930			71,930
Common Stock		32,346			32,536			29,615
Additional Paid-In Capital		572,968			578,087			503,325
Retained Earnings		380,182			361,846			309,999
Accumulated Other Comprehensive Loss		(54,910	)		(35,822	)		(36,429	)
Total Shareholders’ Equity		1,002,516			1,008,577			878,440
Total Liabilities and Shareholders’ Equity	$	8,955,962		$	8,903,506		$	7,953,862

Business First Bancshares, Inc.
Consolidated Statements of Income
(Unaudited)
	Three Months Ended									Nine Months Ended
	September 30,			June 30,			September 30,			September 30,		September 30,
(Dollars in thousands)		2026			2026			2025			2026		2025
Interest Income:
Interest and Fees on Loans	$	113,263		$	111,780		$	106,662		$	334,189	$	313,682
Interest and Dividends on Securities		9,207			9,104			7,554			26,773		21,074
Interest on Federal Funds Sold and Due From Banks		5,047			4,766			4,472			14,699		12,475
Total Interest Income		127,517			125,650			118,688			375,661		347,231
Interest Expense:
Interest on Deposits		41,511			41,251			43,358			125,520		127,343
Interest on Borrowings		5,342			6,555			6,054			16,438		17,587
Total Interest Expense		46,853			47,806			49,412			141,958		144,930
Net Interest Income		80,664			77,844			69,276			233,703		202,301
Provision for Credit Losses		1,938			1,991			3,183			6,207		8,220
Net Interest Income After Provision for Credit Losses		78,726			75,853			66,093			227,496		194,081
Other Income:
Service Charges on Deposit Accounts		3,340			3,197			2,565			9,679		8,058
Gain (Loss) on Sales of Securities		(21	)		(6	)		77			53		29
Gain on Sales of Loans		814			1,583			624			3,738		2,661
Other Income		8,379			9,193			8,405			27,059		28,564
Total Other Income		12,512			13,967			11,671			40,529		39,312
Other Expenses:
Salaries and Employee Benefits		32,582			33,120			27,613			98,741		85,427
Occupancy and Equipment Expense		10,078			8,279			7,284			26,479		21,802
Merger and Conversion-Related Expense		1,395			303			477			3,075		937
Other Expenses		16,410			17,823			13,508			49,166		42,500
Total Other Expenses		60,465			59,525			48,882			177,461		150,666
Income Before Income Taxes		30,773			30,295			28,882			90,564		82,727
Provision for Income Taxes		6,221			6,120			6,026			18,273		17,225
Net Income		24,552			24,175			22,856			72,291		65,502
Preferred Stock Dividends		1,351			1,350			1,351			4,051		4,051
Net Income Available to Common Shareholders	$	23,201		$	22,825		$	21,505		$	68,240	$	61,451

Business First Bancshares, Inc.
Consolidated Net Interest Margin
(Unaudited)
		Three Months Ended
		September 30, 2026								June 30, 2026								September 30, 2025
		Average								Average								Average
		Outstanding			Interest Earned /	Average				Outstanding			Interest Earned /	Average				Outstanding			Interest Earned /	Average
(Dollars in thousands)		Balance			Interest Paid	Yield / Rate				Balance			Interest Paid	Yield / Rate				Balance			Interest Paid	Yield / Rate
Assets
Interest-Earning Assets:
Total Loans	$	6,670,021		$	113,263	6.74	%		$	6,757,776		$	111,780	6.63	%		$	6,036,622		$	106,662	7.01	%
Securities		1,054,664			9,207	3.46	%			1,068,191			9,104	3.42	%			978,502			7,554	3.06	%
Securities Purchased under Agreements to Resell		32,316			359	4.41	%			30,683			335	4.38	%			25,490			330	5.14	%
Interest-Bearing Deposit in Other Banks		533,251			4,688	3.49	%			509,177			4,431	3.49	%			419,413			4,142	3.92	%
Total Interest-Earning Assets	$	8,290,252		$	127,517	6.10	%		$	8,365,827		$	125,650	6.02	%		$	7,460,027		$	118,688	6.31	%
Allowance for Loan Losses		(62,716	)							(63,280	)							(58,468	)
Noninterest-Earning Assets		617,511								614,407								519,600
Total Assets	$	8,845,047		$	127,517				$	8,916,954		$	125,650				$	7,921,159		$	118,688
Liabilities and Shareholders’ Equity
Interest-Bearing Liabilities:
Interest-Bearing Deposits	$	5,729,786		$	41,511	2.87	%		$	5,739,241		$	41,251	2.88	%		$	5,122,136		$	43,358	3.36	%
Subordinated Debt		114,250			1,874	6.51	%			112,252			1,778	6.35	%			92,624			1,235	5.29	%
Subordinated Debt – Trust Preferred Securities		9,682			185	7.56	%			9,670			178	7.40	%			5,000			100	7.93	%
Advances from Federal Home Loan Bank (FHLB)		300,381			3,120	4.12	%			441,012			4,457	4.05	%			424,287			4,547	4.25	%
Other Borrowings		24,958			163	2.59	%			22,206			142	2.58	%			26,176			172	2.61	%
Total Interest-Bearing Liabilities	$	6,179,057		$	46,853	3.01	%		$	6,324,381		$	47,806	3.03	%		$	5,670,223		$	49,412	3.46	%
Noninterest-Bearing Liabilities:
Noninterest-Bearing Deposits	$	1,573,300							$	1,518,400							$	1,315,064
Other Liabilities		76,427								71,223								73,794
Total Noninterest-Bearing Liabilities		1,649,727								1,589,623								1,388,858
Shareholders’ Equity:
Common Shareholders’ Equity		944,333								931,020								790,148
Preferred Equity		71,930								71,930								71,930
Total Shareholders’ Equity		1,016,263								1,002,950								862,078
Total Liabilities and Shareholders’ Equity	$	8,845,047							$	8,916,954							$	7,921,159
Net Interest Spread						3.09	%							2.99	%							2.85	%
Net Interest Income				$	80,664							$	77,844							$	69,276
Net Interest Margin						3.86	%							3.73	%							3.68	%
Overall Cost of Funds						2.40	%							2.44	%							2.81	%
NOTE: Average outstanding balances are determined utilizing daily averages and an actual day count convention.

Business First Bancshares, Inc.
Consolidated Net Interest Margin
(Unaudited)
		Nine Months Ended
		September 30, 2026						September 30, 2025
		Average						Average
		Outstanding		Interest Earned /	Average			Outstanding		Interest Earned /	Average
(Dollars in thousands)		Balance		Interest Paid	Yield / Rate			Balance		Interest Paid	Yield / Rate
Assets
Interest-Earning Assets:
Total Loans	$	6,708,583	$	334,189	6.66%		$	6,001,647	$	313,682	6.99%
Securities		1,062,728		26,773	3.37%			946,961		21,074	2.98%
Securities Purchased under Agreements to Resell		29,906		996	4.45%			35,740		1,382	5.17%
Interest-Bearing Deposit in Other Banks		533,540		13,703	3.43%			361,760		11,093	4.10%
Total Interest-Earning Assets		8,334,757		375,661	6.03%			7,346,108		347,231	6.32%
Allowance for Loan Losses		(62,191)						(56,718)
Noninterest-Earning Assets		613,518						536,438
Total Assets	$	8,886,084	$	375,661			$	7,825,828	$	347,231
Liabilities and Shareholders’ Equity
Interest-Bearing Liabilities:
Interest-Bearing Deposits	$	5,783,862	$	125,520	2.90%		$	5,103,928	$	127,343	3.34%
Subordinated Debt		106,303		4,872	6.13%			94,169		3,732	5.30%
Subordinated Debt – Trust Preferred Securities		10,334		516	6.68%			5,000		299	8.03%
Advances from Federal Home Loan Bank (FHLB)		346,337		10,615	4.10%			411,444		13,136	4.27%
Other Borrowings		22,416		435	2.59%			21,699		420	2.59%
Total Interest-Bearing Liabilities	$	6,269,252	$	141,958	3.03%		$	5,636,240	$	144,930	3.44%
Noninterest-Bearing Liabilities:
Noninterest-Bearing Deposits	$	1,537,842					$	1,284,745
Other Liabilities		74,515						67,954
Total Noninterest-Bearing Liabilities		1,612,357						1,352,699
Shareholders’ Equity:
Common Shareholders’ Equity		932,545						764,959
Preferred Equity		71,930						71,930
Total Shareholders’ Equity		1,004,475						836,889
Total Liabilities and Shareholders’ Equity	$	8,886,084					$	7,825,828
Net Interest Spread					3.00%						2.88%
Net Interest Income			$	233,703					$	202,301
Net Interest Margin					3.75%						3.68%
Overall Cost of Funds					2.43%						2.80%
NOTE: Average outstanding balances are determined utilizing daily averages and an actual day count convention.

Business First Bancshares, Inc.
Non-GAAP Measures
(Unaudited)
	Three Months Ended										Nine Months Ended
	September 30,			June 30,			September 30,				September 30,			September 30,
(Dollars in thousands, except per share data)		2026			2026			2025				2026			2025
Interest Income:
Interest income	$	127,517		$	125,650		$	118,688			$	375,661		$	347,231
Core interest income		127,517			125,650			118,688				375,661			347,231
Interest Expense:
Interest expense		46,853			47,806			49,412				141,958			144,930
Core interest expense		46,853			47,806			49,412				141,958			144,930
Provision for Credit Losses: (b)
Provision for credit losses		1,938			1,991			3,183				6,207			8,220
Core provision expense		1,938			1,991			3,183				6,207			8,220
Other Income:
Other income		12,512			13,967			11,671				40,529			39,312
Gain on former bank premises and equipment		–			–			–				(28	)		(155	)
Loss (gain) on sale of securities		21			6			(77	)			(53	)		(29	)
Gain on extinguishment/redemption of debt		–			(545	)		–				(545	)		(630	)
Gain on sale of branch		–			–			–				–			(3,360	)
Core other income		12,533			13,428			11,594				39,903			35,138
Other Expense:
Other expense		60,465			59,525			48,882				177,461			150,666
Acquisition-related expenses (2)		(3,538	)		(1,169	)		(1,157	)			(6,934	)		(2,406	)
Core conversion expenses		–			–			(439	)			–			(1,663	)
Tax credit – ERC		–			–			1,997				–			1,997
Core other expense		56,927			58,356			49,283				170,527			148,594
Pre-Tax Income: (a)
Pre-tax income		30,773			30,295			28,882				90,564			82,727
Gain on former bank premises and equipment		–			–			–				(28	)		(155	)
Loss (gain) on sale of securities		21			6			(77	)			(53	)		(29	)
Gain on extinguishment/redemption of debt		–			(545	)		–				(545	)		(630	)
Gain on sale of branch		–			–			–				–			(3,360	)
Acquisition-related expenses (2)		3,538			1,169			1,157				6,934			2,406
Core conversion expenses		–			–			439				–			1,663
Tax credit – ERC		–			–			(1,997	)			–			(1,997	)
Core pre-tax income		34,332			30,925			28,404				96,872			80,625
Provision for Income Taxes: (1)
Provision for income taxes		6,221			6,120			6,026				18,273			17,225
Tax on gain on former bank premises and equipment		–			–			–				(6	)		(33	)
Tax on loss (gain) on sale of securities		5			1			(16	)			(11	)		(6	)
Tax on gain on extinguishment/redemption of debt		–			(115	)		–				(115	)		(133	)
Tax on gain on sale of branch		–			–			–				–			(833	)
Tax on acquisition-related expenses (2)		743			239			157				1,301			403
Tax on core conversion expenses		–			–			93				–			352
Tax on employee retention tax credit		–			–			(422	)			–			(422	)
Core provision for income taxes		6,969			6,245			5,838				19,442			16,553
Preferred Dividends:
Preferred dividends		1,351			1,350			1,351				4,051			4,051
Core preferred dividends	$	1,351		$	1,350		$	1,351			$	4,051		$	4,051
Net Income Available to Common Shareholders:
Net income available to common shareholders	$	23,201		$	22,825		$	21,505			$	68,240		$	61,451
Gain on former bank premises and equipment, net of tax		–			–			–				(22	)		(122	)
Loss (gain) on sale of securities, net of tax		16			5			(61	)			(42	)		(23	)
Gain on extinguishment/redemption of debt, net of tax		–			(430	)		–				(430	)		(497	)
Gain on sale of branch, net of tax		–			–			–				–			(2,527	)
Acquisition-related expenses (2), net of tax		2,795			930			1,000				5,633			2,003
Core conversion expenses, net of tax		–			–			346				–			1,311
Tax credit – ERC, net of tax		–			–			(1,575	)			–			(1,575	)
Core net income available to common shareholders		26,012			23,330			21,215				73,379			60,021
Pre-tax, pre-provision earnings available to common shareholders (a+b) (3)		32,711			32,286			32,065				96,771			90,947
Gain on former bank premises and equipment		–			–			–				(28	)		(155	)
Loss (gain) on sale of securities		21			6			(77	)			(53	)		(29	)
Gain on extinguishment/redemption of debt		–			(545	)		–				(545	)		(630	)
Gain on sale of branch		–			–			–				–			(3,360	)
Acquisition-related expenses (2)		3,538			1,169			1,157				6,934			2,406
Core conversion expenses		–			–			439				–			1,663
Employee retention tax credit		–			–			(1,997	)			–			(1,997	)
Core pre-tax, pre-provision earnings	$	36,270		$	32,916		$	31,587			$	103,079		$	88,845
Average Diluted Common Shares Outstanding		32,730,923			32,763,608			29,656,639				32,766,628			29,495,049
Diluted Earnings Per Common Share:
Diluted earnings per common share	$	0.71		$	0.70		$	0.73			$	2.08		$	2.08
Gain on former bank premises and equipment, net of tax		—			—			—				—			—
Loss (gain) on sale of securities, net of tax		—			—			—				—			—
Gain on extinguishment/redemption of debt, net of tax		—			(0.01	)		—				(0.01	)		(0.02	)
Gain on sale of branch, net of tax		—			—			—				—			(0.09	)
Acquisition-related expenses (2), net of tax		0.08			0.02			0.03				0.17			0.07
Core conversion expenses, net of tax		—			—			0.01				—			0.04
Tax credit – ERC, net of taxes		—			—			(0.05	)			—			(0.05	)
Core diluted earnings per common share	$	0.79		$	0.71		$	0.72			$	2.24		$	2.03
Pre-tax, pre-provision profit diluted earnings per common share	$	1.00		$	0.99		$	1.08			$	2.95		$	3.08
Gain on former bank premises and equipment		—			—			—				—			(0.01	)
Loss (gain) on sale of securities		—			—			—				—			—
Gain on extinguishment/redemption of debt		—			(0.02	)		—				(0.02	)		(0.02	)
Gain on sale of branch		—			—			—				—			(0.11	)
Acquisition-related expenses (2)		0.11			0.04			0.04				0.21			0.08
Core conversion expenses		—			—			0.02				—			0.06
Tax credit – ERC		—			—			(0.07	)			—			(0.07	)
Core pre-tax, pre-provision diluted earnings per common share	$	1.11		$	1.01		$	1.07			$	3.14		$	3.01
(1) Tax rates, exclusive of certain nondeductible merger-related expenses and goodwill, utilized were 21.129% for 2026 and 2025. These rates approximated the marginal tax rates.
(2) Includes merger and conversion-related expenses and salary and employee benefits.
(3) Before preferred dividends.

Business First Bancshares, Inc.
Non-GAAP Measures
(Unaudited)
	September 30,			June 30,			September 30,
(Dollars in thousands, except per share data)		2026			2026			2025
Total Shareholders’ (Common) Equity:
Total shareholders’ equity	$	1,002,516		$	1,008,577		$	878,440
Preferred stock		(71,930	)		(71,930	)		(71,930	)
Total common shareholders’ equity		930,586			936,647			806,510
Goodwill		(131,743	)		(135,222	)		(121,146	)
Core deposit and customer intangible		(31,983	)		(33,267	)		(15,136	)
Total tangible common equity	$	766,860		$	768,158		$	670,228
Total Assets:
Total assets	$	8,955,962		$	8,903,506		$	7,953,862
Goodwill		(131,743	)		(135,222	)		(121,146	)
Core deposit and customer intangible		(31,983	)		(33,267	)		(15,136	)
Total tangible assets	$	8,792,236		$	8,735,017		$	7,817,580
Common shares outstanding		32,345,723			32,535,659			29,615,370
Book value per common share	$	28.77		$	28.79		$	27.23
Tangible book value per common share		23.71			23.61			22.63
Common equity to total assets		10.39	%		10.52	%		10.14	%
Tangible common equity to tangible assets		8.72	%		8.79	%		8.57	%

Business First Bancshares, Inc.
Non-GAAP Measures
(Unaudited)
	Three Months Ended							Nine Months Ended
	September 30,		June 30,		September 30,			September 30,		September 30,
(Dollars in thousands, except per share data)	2026		2026		2025			2026		2025
Total Quarterly Average Assets	8,845,047		8,916,954		7,921,159			8,886,084		7,825,828
Total Quarterly Average Common Equity	944,333		931,020		790,148			932,545		764,959
Net Income Available to Common Shareholders:
Net income available to common shareholders	23,201		22,825		21,505			68,240		61,451
Gain on former bank premises and equipment, net of tax	–		–		–			(22	)	(122	)
Loss (gain) on sale of securities, net of tax	16		5		(61	)		(42	)	(23	)
Gain on extinguishment of debt, net of tax	–		(430	)	–			(430	)	(497	)
Gain on sale of branch, net of tax	–		–		–			–		(2,527	)
Acquisition-related expenses, net of tax	2,795		930		1,000			5,633		2,003
Core conversion expenses, net of tax	–		–		346			–		1,311
Core net income available to common shareholders	26,012		23,330		21,215			73,379		60,021
Return to common shareholders on average assets (annualized) (2)	1.04	%	1.03	%	1.08	%		1.03	%	1.05	%
Core return on average assets (annualized) (2)	1.17	%	1.05	%	1.06	%		1.10	%	1.03	%
Return to common shareholders on average common equity (annualized) (2)	9.75	%	9.83	%	10.80	%		9.78	%	10.74	%
Core return on average common equity (annualized) (2)	10.93	%	10.05	%	10.65	%		10.52	%	10.49	%
Interest Income:
Interest income	127,517		125,650		118,688			375,661		347,231
Core interest income	127,517		125,650		118,688			375,661		347,231
Interest Expense:
Interest expense	46,853		47,806		49,412			141,958		144,930
Core interest expense	46,853		47,806		49,412			141,958		144,930
Other Income:
Other income	12,512		13,967		11,671			40,529		39,312
Gain on former bank premises and equipment	–		–		–			(28	)	(155	)
Loss (gain) on sale of securities	21		6		(77	)		(53	)	(29	)
Gain on extinguishment of debt	–		(545	)	–			(545	)	(630	)
Gain on sale of branch	–		–		–			–		(3,360	)
Core other income	12,533		13,428		11,594			39,903		35,138
Other Expense:
Other expense	60,465		59,525		48,882			177,461		150,666
Acquisition-related expenses	(3,538	)	(1,169	)	(1,157	)		(6,934	)	(2,406	)
Core conversion expenses	–		–		(439	)		–		(1,663	)
Core other expense	56,927		58,356		49,283			170,527		148,594
Efficiency Ratio:
Other expense (a)	60,465		59,525		48,882			177,461		150,666
Core other expense (c)	56,927		58,356		49,283			170,527		148,594
Net interest and other income (1) (b)	93,197		91,817		80,870			274,179		241,584
Core net interest and other income (1) (d)	93,197		91,272		80,870			273,606		237,439
Efficiency ratio (a/b)	64.88	%	64.83	%	60.45	%		64.72	%	62.37	%
Core efficiency ratio (c/d)	61.08	%	63.94	%	60.94	%		62.33	%	62.58	%
Total Average Interest-Earnings Assets	8,290,252		8,365,827		7,460,027			8,334,757		7,346,108
Net Interest Income:
Net interest income	80,664		77,844		69,276			233,703		202,301
Loan discount accretion	(1,221	)	(995	)	(1,111	)		(3,355	)	(2,671	)
Net interest income excluding loan discount accretion	79,443		76,849		68,165			230,348		199,630
Net interest margin (2)	3.86	%	3.73	%	3.68	%		3.75	%	3.68	%
Net interest margin excluding loan discount accretion (2)	3.80	%	3.68	%	3.63	%		3.70	%	3.63	%
Net interest spread (2)	3.09	%	2.99	%	2.85	%		3.00	%	2.88	%
Net interest spread excluding loan discount accretion (2)	3.04	%	2.94	%	2.80	%		2.94	%	2.83	%
(1) Excludes gains/losses on sales of securities.
(2) Calculated utilizing an actual day count convention.

CONTACT: Media Contact: Misty Albrecht b1BANK
225.286.7879
media@b1BANK.com

TERRE HAUTE, Ind., Oct. 26, 2026 (GLOBE NEWSWIRE) — Hallador Energy Company (Nasdaq: HNRG) (“Hallador” or the “Company”), will host a conference call on Monday, November 9, 2026, at 5:00 p.m. Eastern time to discuss its financial results for the third quarter ended September 30, 2026. The Company’s results will be reported in a press release prior to the call.

Hallador’s management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions prior to the call by emailing the Company’s investor relations team, Elevate IR, at HNRG@elevate-ir.com.

Date: Monday, November 9, 2026
Time: 5:00 p.m. Eastern time
Dial-in registration link: here
Live webcast registration link: here

The conference call will also be broadcast live and available for replay in the investor relations section of the Company’s website at www.halladorenergy.com.

About Hallador Energy Company

Hallador Energy Company (Nasdaq: HNRG) is a vertically-integrated Independent Power Producer (IPP) based in Terre Haute, Indiana. The Company has two core businesses: Hallador Power Company, LLC, which produces electricity and provides accredited capacity at its one-Gigawatt (GW) Merom Generating Station, and Sunrise Coal, LLC, which produces and supplies fuel to the Merom Generating Station and other companies. To learn more about Hallador, visit the Company’s website at www.halladorenergy.com.

Investor Relations Contact

Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
HNRG@elevate-ir.com

Media Relations Contact

TrailRunner International
halladorenergymedia@trailrunnerint.com

WARRENVILLE, Ill., Oct. 26, 2026 (GLOBE NEWSWIRE) — Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today announced the award of multiple Air Pollution Control (APC) contract amendments valued at approximately $3.3 million for utility and industrial customers.

An order was received from a domestic customer for a project involving two new natural gas-fired turbines for an industrial site involved with natural gas infrastructure. The original scope was to supply Selective Catalytic Reduction (SCR) systems with UDI Urea Direct Injection reagent delivery systems utilizing a multi-function catalyst to provide high levels of nitrogen oxide (NO_x) reduction, as well as reducing carbon monoxide (CO) and volatile organic compounds (VOC) to meet the site requirements. The UDI system eliminates the hazards associated with the transport, storage and handling of anhydrous or aqueous ammonia. The expanded scope includes additional process and interconnection equipment to support the original SCR scope.

In Europe, three orders were received on separate SCR projects to provide additional services and equipment.

“We are pleased to announce these orders which increase our current backlog to approximately $20 million,” said Ramesh Nuggihalli, President and CEO. “We are actively pursuing additional APC contracts that are likely to be awarded in the next 60-90 days. We continue to see growth in our traditional power and industrial markets while pursuing new opportunities, including potential SCR projects supporting data center power infrastructure.”

About Fuel Tech

Fuel Tech develops and commercializes state-of-the-art proprietary technologies for air pollution control, process optimization, water treatment, and advanced engineering services. These technologies enable customers to operate in a cost-effective and environmentally sustainable manner. Fuel Tech is a leader in nitrogen oxide (NOx) reduction and particulate control technologies, and its solutions have been installed on over 2,100 utility, industrial and municipal units worldwide. The Company’s chemical technologies improve the efficiency, reliability, fuel flexibility, boiler heat rate, and environmental status of combustion units by controlling slagging, fouling, corrosion and opacity. This includes Fuel Tech’s advanced TIFI^® Targeted In-Furnace Injection™ technology which offers an innovative solution to fireside treatment on boilers using coal, oil or biomass. Water treatment technologies include DGI^® Dissolved Gas Infusion Systems which utilize a patented saturator and a patent-pending channel injector to deliver supersaturated oxygen solutions and other gas-water combinations to target process applications or environmental issues. This infusion process has a variety of applications in the water and wastewater industries, including remediation, aeration, biological treatment and wastewater odor management. Many of Fuel Tech’s products and services rely heavily on the Company’s exceptional Computational Fluid Dynamics modeling capabilities, which are enhanced by internally developed, high-end visualization software. For more information, visit Fuel Tech’s web site at ftek.com.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” as defined in Section 21E of the Securities Exchange Act of 1934, as amended, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and reflect Fuel Tech’s current expectations regarding future growth, results of operations, cash flows, performance and business prospects, and opportunities, as well as assumptions made by, and information currently available to, our management. Fuel Tech has tried to identify forward-looking statements by using words such as “anticipate,” “believe,” “plan,” “expect,” “estimate,” “intend,” “will,” and similar expressions, but these words are not the exclusive means of identifying forward-looking statements. These statements are based on information currently available to Fuel Tech and are subject to various risks, uncertainties, and other factors, including, but not limited to, those discussed in Fuel Tech’s Annual Report on Form 10-K in Item 1A under the caption “Risk Factors,” and subsequent filings under the Securities Exchange Act of 1934, as amended, which could cause Fuel Tech’s actual growth, results of operations, financial condition, cash flows, performance and business prospects and opportunities to differ materially from those expressed in, or implied by, these statements. Fuel Tech undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements contained herein to reflect future events, developments, or changed circumstances or for any other reason. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including those detailed in Fuel Tech’s filings with the Securities and Exchange Commission.

CONTACT:

Devin Sullivan
Managing Director 
The Equity Group Inc.
devin.sullivan@theequitygroup.com

Conor Rodriguez
Associate
Conor.Rodriguez@theequitygroup.com

Peer-Reviewed Scientific Reports Data & Academic Collaboration Show Potent Anti-Tumor Activity, EMT Reversal, & Sequential Chemo-Sensitization; Phase 1b First-In-Human Study Planned for Q1 2027

MELBOURNE, Australia, Oct. 26, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced new preclinical data supporting the potential of its lead asset, PRP (a proprietary fixed-ratio 1:6 intravenous formulation of trypsinogen and chymotrypsinogen), to address chemotherapy resistance in pancreatic cancer.

In collaborative research led by Dr. Maria Belén Toledo at the Universities of Jaén and Granada, PRP was shown to remodel the resistant cellular state in pancreatic cancer models with acquired chemotherapy resistance. The study used a sequential design (chemoresistant cells → PRP pre-treatment → chemotherapy challenge) and demonstrated that PRP functions as a resistance-modulating intervention rather than a conventional cytotoxic agent. Key preclinical findings:

• Proliferation and survival: PRP monotherapy reduced cancer cell proliferation by ~50–54% and suppressed long-term clonogenic survival by up to 59%.
• Metastatic behavior: Migration limited to 21–57% wound closure (vs. 100% in untreated controls); invasive capacity reduced by 47–81%.
• EMT reversal: Strong epithelial differentiation with E-cadherin upregulated up to 5.29-fold and EPCAM up to 4.39-fold; mesenchymal drivers Vimentin reduced to ~0.31–0.32-fold and Snail to 0.28–0.62-fold.
• Pathway effects: Significant downregulation of TGF-β/SMAD signaling, induction of pro-apoptotic BAX (up to 2.74-fold), and suppression of oncogenic stemness drivers MYC and SOX2 (down to 0.11–0.22-fold in resistant cells).
• Combination synergy: PRP plus TGF-β inhibition further amplified responses, including 80% invasion inhibition and stronger apoptotic signaling.

These results complement the Company’s recent peer-reviewed pilot study published in Scientific Reports (Nature Publishing Group), which reported an 85.9% reduction in mean tumor weight in an orthotopic pancreatic (Pan 02) model at the higher dose, ~50% tumor-weight inhibition in an ovarian (A2780) model, anti-angiogenic activity, near-complete blockade of invasion in select lines, and EMT reversal. The Pan 02 cancer cell line is particularly noteworthy since it is a syngeneic (genetically identical or similar) tumor model conducted in immunocompetent mice and is clinically relevant for patients where cytotoxic agents induce immunosuppression and are at risk of infection—one of the main causes of death for cancer patients. Conversely, PRP reduces chemoresistance whilst enhancing immunorecognition.

In addition, earlier orthotopic and patient-derived xenograft data have also shown >90% mean tumor growth inhibition and >2.5-fold median survival extension in advanced PDAC models, with reduced metastatic burden and tumor microenvironment remodeling.

^{In vivo anti-tumor activity of PRP}

^{(A) Images of excised tumors at study termination of orthotropic pancreatic tumors. Mean tumor weight at termination day after daily I.V. injection of PBS, T/C 27.5/165 (mg/kg) or T/C 83.3/500 (mg/kg) (∗P < 0.05). (B) Images of excised tumors at study termination of orthotropic ovarian tumors. Mean tumor weight at termination day after daily I.V. injection of PBS, T/C 9.1/54 (mg/kg) or T/C 27.5/165 (mg/kg) (∗P < 0.05)}

PRP’s differentiation-based mechanism—targeting cancer stem cells, EMT, fibrosis, and metastatic dissemination—is distinct from and potentially complementary to emerging RAS-targeted approaches. Revolution Medicines’ daraxonrasib (RASONQUE), recently FDA-approved for metastatic pancreatic adenocarcinoma, has set a clinical benchmark with median overall survival of 13.2 months versus 6.6–6.7 months for chemotherapy in the Phase 3 RASolute 302 trial. Erasca’s pan-RAS molecular glue ERAS-0015 similarly focuses on oncogenic RAS signaling. PRP does not inhibit RAS and is not genotype-restricted; its preclinical package of deep tumor control, fewer metastases, a less fibrotic microenvironment, and chemo re-sensitization, addresses residual biology that RAS pathway blockade does not directly target. Limited prior compassionate-use experience with related proenzyme formulations has shown signals of prolonged survival in advanced solid-tumor patients with a favorable safety profile. PRP holds FDA Orphan Drug Designation for pancreatic cancer.

“These findings are highly significant as we progress PRP to our world-first Phase 1b First-in-Human study for advanced solid-tumor patients planned for Q1 2027,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “We envision PRP as a long-term, metronomic therapy that minimizes the threat of recurrence while enabling patients to better respond to standard treatments when resistance becomes critical. The data positions PRP as a potential sequential or combination partner to RAS inhibitors from companies such as Revolution Medicines and Erasca, addressing biology—cancer stem cells, EMT, fibrosis, and metastatic spread—that those agents do not primarily target.”

The Company continues advancing manufacturing, pharmacokinetics assay validation, and clinical preparations for the multicenter, open-label Phase 1b study (dose escalation followed by expansion) expected to enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at sites in Australia.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com

Investor Contact:
irteam@propanc.com

LAVAL, Quebec, Oct. 26, 2026 (GLOBE NEWSWIRE) — Savaria Corporation (“Savaria”) (TSX: SIS), one of the global leaders in the accessibility industry, announces it will release its financial results for the third quarter of 2026 after market closes on November 4, 2026. Savaria’s management will hold an investor conference call and webcast at 8:30 a.m. Eastern Daylight Time (EDT) on Thursday, November 5, 2026. Investors and members of the media are invited to participate on a listen-only basis.

Conference call access:

https://register-conf.media-server.com/register/BIa519517032e44335925d530987479cd6

To access the conference call, you must register online and choose the method to join the call, either by dialing the number provided to you or by entering your phone number to receive a call from the system.

Webcast URL (EN): https://edge.media-server.com/mmc/p/4rzdczxq

About Savaria Corporation

Savaria Corporation (corp.savaria.com) is one of the global leaders in the accessibility industry. It provides accessibility solutions for the physically challenged to increase their comfort, their mobility and their independence. Its product line is one of the most comprehensive on the market. Savaria designs, manufactures, distributes and installs accessibility equipment, such as elevators for home and commercial use, stairlifts for straight and curved stairs, vertical and inclined wheelchair lifts and dumbwaiters. In addition, Savaria manufactures and markets a comprehensive selection of pressure management products, medical beds, as well as an extensive line of medical equipment and solutions for the safe movement of patients, such as transfer, lifting and repositioning aids. The Corporation operates a sales network of dealers worldwide and direct sales offices in North America, Europe (UK, Netherlands, Switzerland, Italy, Germany, Poland and Czech Republic) and Australia. Savaria employs approximately 2,600 people globally and its plants are located across Canada, the United States, Mexico, Europe and China.

For further information:
Sébastien Bourassa President and CEO 1. 800.661.5112  sb@savaria.com		Stephen Reitknecht, CPA, CA Chief Financial Officer 1.800.661.5112, ext. 3370 sreitknecht@savaria.com

Facebook : https://www.facebook.com/savariabettermobility
Instagram :https://www.instagram.com/savariacorp/
LinkedIn: https://ca.linkedin.com/company/savaria 

LEI: 213800NNT42FFIZB1T09 
26 October 2026

This announcement corrects the announcement released on 23 October 2026, which incorrectly stated that the total number of Ordinary Shares with voting rights was 11,081,960. The correct figure is 111,081,960. All other information in the announcement remains unchanged.

Transactions in Own Shares

Foresight Group Holdings Limited (“Foresight”, the “Group”), a leading investment manager in real assets and providing capital for growth, announces that, in accordance with the terms of its current share buyback programme announced on 10 April 2025 (the “Share Buyback”), the Group purchased the following number of its ordinary shares of £nil par value (“Ordinary Shares”) each through JOH Berenberg, Gossler & Co KG (which is trading for these purposes as Berenberg) (“Berenberg”).

Date of purchase:	16 October 2026
Aggregate number of Ordinary Shares purchased:	10,000
Lowest price paid per share (GBp):	444.50
Highest price paid per share (GBp):	448.50
Volume weighted average price paid per share (GBp):	447.165250

Date of purchase:	19 October 2026
Aggregate number of Ordinary Shares purchased:	10,000
Lowest price paid per share (GBp):	443.50
Highest price paid per share (GBp):	446.00
Volume weighted average price paid per share (GBp):	444.519400

Date of purchase:	20 October 2026
Aggregate number of Ordinary Shares purchased:	10,000
Lowest price paid per share (GBp):	437.00
Highest price paid per share (GBp):	448.50
Volume weighted average price paid per share (GBp):	442.316900

Date of purchase:	21 October 2026
Aggregate number of Ordinary Shares purchased:	10,000
Lowest price paid per share (GBp):	446.00
Highest price paid per share (GBp):	450.50
Volume weighted average price paid per share (GBp):	448.680800

Date of purchase:	22 October 2026
Aggregate number of Ordinary Shares purchased:	10,000
Lowest price paid per share (GBp):	449.50
Highest price paid per share (GBp):	456.50
Volume weighted average price paid per share (GBp):	453.564500

Once settled, the purchased shares will be held by the Group in treasury, which means they will have no voting rights while they are held in treasury. Under the current Buyback Programme, an aggregate of 7,728,732 Ordinary Shares have been bought back.

As a result of the above, of the Group’s 112,347,803 Ordinary Shares currently in issue, a total of 111,081,960 have voting rights and 1,265,843 held in treasury and are therefore non-voting. The total number of voting shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in the Group under the FCA’s Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of the UK version of Regulation (EU) No. 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback.

Individual information:

Number of ordinary shares purchased	Transaction price (GBp share)	Time of transaction (UK Time)	Trading Venue
384	445.000	16/10/2026 08:00:23	LSE
384	444.500	16/10/2026 08:17:41	LSE
416	446.000	16/10/2026 08:17:49	LSE
1020	446.500	16/10/2026 08:37:24	LSE
185	446.500	16/10/2026 08:41:40	LSE
195	446.500	16/10/2026 08:42:08	LSE
1764	446.500	16/10/2026 09:00:52	LSE
1881	448.000	16/10/2026 09:05:59	LSE
191	448.000	16/10/2026 09:06:05	LSE
191	448.000	16/10/2026 09:06:10	LSE
1968	447.500	16/10/2026 09:06:42	LSE
1421	448.500	16/10/2026 09:09:48	LSE
378	446.000	19/10/2026 08:00:15	LSE
341	446.000	19/10/2026 08:00:15	LSE
32	444.500	19/10/2026 08:21:17	LSE
189	444.500	19/10/2026 08:34:08	LSE
765	445.000	19/10/2026 08:48:12	LSE
614	445.000	19/10/2026 08:48:12	LSE
207	445.000	19/10/2026 09:46:06	LSE
514	444.500	19/10/2026 09:47:26	LSE
338	443.500	19/10/2026 09:50:33	LSE
189	444.000	19/10/2026 10:12:27	LSE
1700	443.500	19/10/2026 10:13:59	LSE
223	443.500	19/10/2026 10:13:59	LSE
1234	443.500	19/10/2026 10:13:59	LSE
455	444.500	19/10/2026 11:17:32	LSE
1075	445.500	19/10/2026 11:37:26	LSE
189	446.000	19/10/2026 11:40:57	LSE
189	446.000	19/10/2026 12:02:03	LSE
313	445.500	19/10/2026 12:02:51	LSE
255	444.500	19/10/2026 12:58:47	LSE
714	444.500	19/10/2026 12:58:47	LSE
86	444.000	19/10/2026 13:00:04	LSE
189	445.000	20/10/2026 08:18:26	LSE
189	444.500	20/10/2026 08:18:46	LSE
499	444.000	20/10/2026 08:33:23	LSE
229	441.500	20/10/2026 09:26:33	LSE
349	441.500	20/10/2026 09:26:33	LSE
149	439.500	20/10/2026 09:57:53	LSE
262	439.500	20/10/2026 09:57:55	LSE
295	439.500	20/10/2026 09:57:55	LSE
428	440.000	20/10/2026 10:00:03	LSE
276	440.000	20/10/2026 10:00:03	LSE
311	438.000	20/10/2026 10:45:25	LSE
340	438.500	20/10/2026 10:56:55	LSE
1182	440.000	20/10/2026 11:24:38	LSE
276	439.500	20/10/2026 11:41:50	LSE
312	437.500	20/10/2026 13:03:44	LSE
195	437.000	20/10/2026 13:35:15	LSE
312	438.500	20/10/2026 13:57:55	LSE
250	438.000	20/10/2026 13:58:06	LSE
189	438.000	20/10/2026 14:00:40	LSE
572	442.500	20/10/2026 14:43:02	LSE
256	442.000	20/10/2026 14:43:25	LSE
189	445.500	20/10/2026 14:51:27	LSE
383	445.000	20/10/2026 14:52:59	LSE
549	448.500	20/10/2026 15:30:03	LSE
500	448.000	20/10/2026 15:30:09	LSE
965	446.500	20/10/2026 15:30:29	LSE
354	448.500	20/10/2026 15:34:24	LSE
200	450.500	21/10/2026 08:05:40	LSE
573	450.000	21/10/2026 08:09:14	LSE
886	450.000	21/10/2026 08:15:15	LSE
258	449.500	21/10/2026 08:36:13	LSE
270	449.000	21/10/2026 08:41:11	LSE
186	448.500	21/10/2026 08:41:44	LSE
380	448.500	21/10/2026 09:12:57	LSE
228	447.500	21/10/2026 09:23:00	LSE
503	447.500	21/10/2026 09:23:00	LSE
1216	446.000	21/10/2026 09:41:28	LSE
206	447.000	21/10/2026 09:58:28	LSE
128	447.000	21/10/2026 09:58:28	LSE
1757	448.000	21/10/2026 10:06:55	LSE
1361	448.500	21/10/2026 10:14:52	LSE
246	448.500	21/10/2026 10:24:22	LSE
761	450.500	21/10/2026 10:24:48	LSE
200	450.500	21/10/2026 10:24:48	LSE
573	450.500	21/10/2026 08:05:40	LSE
886	450.000	21/10/2026 08:09:14	LSE
258	450.000	21/10/2026 08:15:15	LSE
270	449.500	21/10/2026 08:36:13	LSE
186	449.000	21/10/2026 08:41:11	LSE
380	448.500	21/10/2026 08:41:44	LSE
228	448.500	21/10/2026 09:12:57	LSE
503	447.500	21/10/2026 09:23:00	LSE
1216	447.500	21/10/2026 09:23:00	LSE
206	446.000	21/10/2026 09:41:28	LSE
128	447.000	21/10/2026 09:58:28	LSE
1757	447.000	21/10/2026 09:58:28	LSE
1361	448.000	21/10/2026 10:06:55	LSE
246	448.500	21/10/2026 10:14:52	LSE
761	448.500	21/10/2026 10:24:22	LSE
186	449.500	22/10/2026 08:36:03	LSE
186	449.500	22/10/2026 08:36:08	LSE
745	451.000	22/10/2026 08:57:01	LSE
186	452.500	22/10/2026 09:00:28	LSE
9	452.500	22/10/2026 09:05:00	LSE
177	452.500	22/10/2026 09:05:00	LSE
300	454.000	22/10/2026 09:16:57	LSE
186	453.500	22/10/2026 09:34:32	LSE
206	453.500	22/10/2026 09:34:32	LSE
642	453.500	22/10/2026 09:45:44	LSE
349	453.500	22/10/2026 09:45:44	LSE
100	454.000	22/10/2026 09:53:38	LSE
226	453.000	22/10/2026 10:02:04	LSE
186	453.000	22/10/2026 10:18:20	LSE
186	452.500	22/10/2026 10:20:17	LSE
204	451.500	22/10/2026 10:41:53	LSE
186	453.000	22/10/2026 11:13:45	LSE
189	453.000	22/10/2026 11:15:00	LSE
297	452.500	22/10/2026 11:55:54	LSE
191	452.500	22/10/2026 12:16:48	LSE
255	452.500	22/10/2026 12:16:48	LSE
186	453.000	22/10/2026 13:00:55	LSE
199	453.500	22/10/2026 13:30:20	LSE
352	453.500	22/10/2026 13:45:22	LSE
358	453.500	22/10/2026 13:55:27	LSE
269	453.500	22/10/2026 14:00:33	LSE
85	453.000	22/10/2026 14:13:50	LSE
260	453.000	22/10/2026 14:14:15	LSE
186	453.000	22/10/2026 14:30:32	LSE
188	456.500	22/10/2026 14:59:25	LSE
281	456.000	22/10/2026 15:06:10	LSE
204	456.000	22/10/2026 15:20:04	LSE
400	455.500	22/10/2026 15:26:47	LSE
138	455.500	22/10/2026 15:26:47	LSE
240	455.500	22/10/2026 15:29:09	LSE
400	455.500	22/10/2026 15:29:09	LSE
400	455.500	22/10/2026 15:29:09	LSE
400	455.500	22/10/2026 15:29:09	LSE
262	455.500	22/10/2026 15:29:09	LSE

For further information please contact:

Foresight Group Investors
Ben McGrory
+44 (0) 7443 821577
ir@foresightgroup.eu

Berenberg (Joint Corporate Broker)
James Felix / John Welch / Dan Gee-Summons
+44 (0) 203 753 7800

H-Advisors Maitland
Sam Cartwright / Audrey Da Costa
+44 (0) 782 725 4561 / +44 (0) 781 710 5562
Foresight@h-advisors.global

About Foresight Group Holdings Limited
Founded in 1984, Foresight is a leading investment manager in real assets and capital for growth, operating across the UK, Europe, and Australia.
With decades of experience, Foresight offers investors access to attractive investment opportunities at the forefront of change. Foresight actively builds and grows investment solutions to support the energy transition, decarbonise industry, enhance nature recovery and realise the economic potential of ambitious companies.

A constituent of the FTSE 250 index, Foresight’s diversified investment strategies combine financial and operational skillsets to maximise asset value and provide attractive returns to its investors. Its wide range of private and public funds is complemented with a variety of investment solutions designed for the retail market.

Foresight is united by a shared commitment to build a sustainable future and grow thriving companies and economies.

Visit https://foresight.group for more information.
Follow us on LinkedIn for key updates.